Before acquisition by Celgene, Acetylon spins out some HDAC inhibitor assets into Regenacy
Prior to its previously announced acquisition by Celgene, private biotech Acetylon Pharmaceuticals Inc. is divesting certain assets outside of Celgene’s areas of focus into a new company, Regenacy Pharmaceuticals LLC, which will have exclusive worldwide rights to these select Acetylon programs and related patents.
Drug Discovery Tools
- Drug Discovery Tools
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com